東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

PI3K-mTOR in cancer and cancer therapy

Dey, Nandini.

FindBook

Google Book

Amazon

博客來

PI3K-mTOR in cancer and cancer therapy

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	PI3K-mTOR in cancer and cancer therapy/ edited by Nandini Dey, Pradip De, Brian Leyland-Jones.
其他作者:	Dey, Nandini.
出版者:	Cham :Springer International Publishing : : 2016.,
面頁冊數:	xxiv, 294 p. :ill., digital ;24 cm.
內容註:	PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics -- Part 1: PI3K-mTOR Pathway in Cancers -- The mTOR Complexes in Cancer Cell Metabolism -- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond -- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures -- Resistance to PI3K Pathway Inhibition -- Part 2: PI3K-mTOR Pathway in Cancer Medicine -- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways -- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma -- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies -- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities.
Contained By:	Springer eBooks
標題:	Cancer - Treatment. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-34211-5
ISBN:	9783319342115

PI3K-mTOR in cancer and cancer therapy
PI3K-mTOR in cancer and cancer therapy[electronic resource] /edited by Nandini Dey, Pradip De, Brian Leyland-Jones. - Cham :Springer International Publishing :2016. - xxiv, 294 p. :ill., digital ;24 cm. - Cancer drug discovery and development,2196-9906. - Cancer drug discovery and development..

PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics -- Part 1: PI3K-mTOR Pathway in Cancers -- The mTOR Complexes in Cancer Cell Metabolism -- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond -- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures -- Resistance to PI3K Pathway Inhibition -- Part 2: PI3K-mTOR Pathway in Cancer Medicine -- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways -- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma -- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies -- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities.

In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway's involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.

ISBN: 9783319342115

Standard No.: 10.1007/978-3-319-34211-5doiSubjects--Topical Terms:

618125
Cancer
--Treatment.

LC Class. No.: RC268.4

Dewey Class. No.: 616.994

PI3K-mTOR in cancer and cancer therapy
LDR:03302nmm a2200325 a 4500 001 2041637
003 DE-He213
005 20161205135122.0
006 m d
007 cr nn 008maaau
008 170118s2016 gw s 0 eng d
020 $a 9783319342115 $q (electronic bk.)
020 $a 9783319342092 $q (paper)
024 7 $a 10.1007/978-3-319-34211-5 $2 doi
035 $a 978-3-319-34211-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RC268.4
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.994 $2 23
090 $a RC268.4 $b .P579 2016
245 0 0 $a PI3K-mTOR in cancer and cancer therapy $h [electronic resource] / $c edited by Nandini Dey, Pradip De, Brian Leyland-Jones.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana Press, $c 2016.
300 $a xxiv, 294 p. : $b ill., digital ; $c 24 cm.
490 1 $a Cancer drug discovery and development, $x 2196-9906
505 0 $a PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics -- Part 1: PI3K-mTOR Pathway in Cancers -- The mTOR Complexes in Cancer Cell Metabolism -- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond -- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures -- Resistance to PI3K Pathway Inhibition -- Part 2: PI3K-mTOR Pathway in Cancer Medicine -- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways -- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma -- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies -- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities.
520 $a In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway's involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.
650 0 $a Cancer $x Treatment. $3 618125
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Cancer Research. $3 891172
650 2 4 $a Molecular Medicine. $3 890952
650 2 4 $a Drug Resistance. $3 836316
650 0 $a Cancer $x Molecular aspects. $3 661419
700 1 $a Dey, Nandini. $3 2200372
700 1 $a De, Pradip. $3 1929888
700 1 $a Leyland-Jones, Brian. $3 1359700
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Cancer drug discovery and development. $3 1565408
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-34211-5
950 $a Medicine (Springer-11650)